Peficitinib: Difference between revisions
CSV import |
CSV import |
||
| Line 1: | Line 1: | ||
{{Short description|An overview of the drug Peficitinib}} | |||
{{Drugbox | |||
| verifiedfields = changed | |||
| verifiedrevid = 477002547 | |||
| image = Peficitinib.svg | |||
| image_size = 200px | |||
| image_alt = Chemical structure of Peficitinib | |||
}} | |||
'''Peficitinib''' is a [[Janus kinase inhibitor]] (JAK inhibitor) used in the treatment of [[rheumatoid arthritis]]. It is a small molecule that selectively inhibits the activity of Janus kinases, which are enzymes involved in the signaling pathways of various cytokines and growth factors. | |||
Peficitinib works by inhibiting the | ==Mechanism of Action== | ||
Peficitinib works by inhibiting the activity of Janus kinases, which are crucial for the signaling of several [[cytokines]] involved in the inflammatory process. By blocking these pathways, peficitinib reduces inflammation and the immune response, which are central to the pathophysiology of rheumatoid arthritis. | |||
== | ==Pharmacokinetics== | ||
Peficitinib is administered orally and is absorbed into the bloodstream, where it exerts its effects on the immune system. The drug undergoes metabolism in the liver and is excreted primarily through the kidneys. | |||
Peficitinib | ==Clinical Use== | ||
Peficitinib is primarily used for the treatment of moderate to severe [[rheumatoid arthritis]] in patients who have had an inadequate response to other disease-modifying antirheumatic drugs (DMARDs). It is often used in combination with other therapies to achieve better control of the disease. | |||
== Side Effects == | ==Side Effects== | ||
Common side effects of peficitinib include [[headache]], [[nausea]], and [[upper respiratory tract infections]]. More serious side effects can include increased risk of infections, [[liver enzyme]] abnormalities, and [[hematological]] changes such as anemia and neutropenia. | |||
==Development and Approval== | |||
Peficitinib was developed as part of ongoing research into JAK inhibitors for the treatment of autoimmune diseases. It has been approved for use in several countries and is undergoing further studies to evaluate its efficacy and safety in other conditions. | |||
==Related pages== | |||
* [[Rheumatoid arthritis]] | |||
* [[Janus kinase inhibitor]] | * [[Janus kinase inhibitor]] | ||
* [[ | * [[Cytokine]] | ||
[[Category:Janus kinase inhibitors]] | [[Category:Janus kinase inhibitors]] | ||
[[Category:Antirheumatic agents]] | |||
Revision as of 03:40, 13 February 2025
An overview of the drug Peficitinib
| Peficitinib | |
|---|---|
| |
| INN | |
| Drug class | |
| Routes of administration | |
| Pregnancy category | |
| Bioavailability | |
| Metabolism | |
| Elimination half-life | |
| Excretion | |
| Legal status | |
| CAS Number | |
| PubChem | |
| DrugBank | |
| ChemSpider | |
| KEGG | |
Peficitinib is a Janus kinase inhibitor (JAK inhibitor) used in the treatment of rheumatoid arthritis. It is a small molecule that selectively inhibits the activity of Janus kinases, which are enzymes involved in the signaling pathways of various cytokines and growth factors.
Mechanism of Action
Peficitinib works by inhibiting the activity of Janus kinases, which are crucial for the signaling of several cytokines involved in the inflammatory process. By blocking these pathways, peficitinib reduces inflammation and the immune response, which are central to the pathophysiology of rheumatoid arthritis.
Pharmacokinetics
Peficitinib is administered orally and is absorbed into the bloodstream, where it exerts its effects on the immune system. The drug undergoes metabolism in the liver and is excreted primarily through the kidneys.
Clinical Use
Peficitinib is primarily used for the treatment of moderate to severe rheumatoid arthritis in patients who have had an inadequate response to other disease-modifying antirheumatic drugs (DMARDs). It is often used in combination with other therapies to achieve better control of the disease.
Side Effects
Common side effects of peficitinib include headache, nausea, and upper respiratory tract infections. More serious side effects can include increased risk of infections, liver enzyme abnormalities, and hematological changes such as anemia and neutropenia.
Development and Approval
Peficitinib was developed as part of ongoing research into JAK inhibitors for the treatment of autoimmune diseases. It has been approved for use in several countries and is undergoing further studies to evaluate its efficacy and safety in other conditions.
